David Reardon, MD
Enriched profileClinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Institute Physician; Alperin Family Chair in Neuro-Oncology; Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute
David Reardon is Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Institute Physician; Alperin Family Chair in Neuro-Oncology; Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 1,226 publications with 63,926 citations (h-index 121); ClinicalTrials.gov lists 28 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists David Reardon as a Highly Cited Researcher (Cross-Field, 2022-2025).
Data verified 7 Sept 2026
Overview
Updated 13 Oct 2026
David A. Reardon is Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute. The public record shows 1,226 publications with 63,926 citations (h-index 121), centered on Glioma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Brain Metastases and Treatment. It also documents an investigator role on 28 registered clinical trials, industry payments reported by 11 companies, 2 NIH-funded awards (2020–2026).
- Most recent indexed publication: 2026 · Nature cancer
- Top research focus: Glioma Diagnosis and Treatment
- 28 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 42 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 454.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 28 registered studies on ClinicalTrials.gov. The most recent:
- CUE-102 in Recurrent Glioblastoma
Sponsor: David Reardon, MD
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Sponsor: Nuvation Bio Inc.
- ASP8374 + Cemiplimab in Recurrent Glioma
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 13 Oct 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim RCV GmbH & Co KGProgram year20253 payments
- Nuvation Bio Inc.Program year20251 payment
- SERVIER PHARMACEUTICALS LLCProgram year20249 payments$15,073openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
67.4%Corticosteroid67.4%Dexamethasone58%Hydrocortisone42%Part D<11 patientsMetabolism & gastrointestinal
32.6%Serotonin-3 Receptor Antagonist32.6%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 13 Oct 2026
2 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
- Understanding and Overcoming T cell Immunosuppression in Glioblastoma
Brigham and Women'S Hospital
FY2026$2,672,918P01CA236749 - Project 1: Neoepitope Vaccine plus Intratumoral Oncolytic Virus for Glioblastoma
Brigham and Women'S Hospital
FY2026$572,180P01CA236749
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A 10-year-long ongoing complete response to vismodegib as first-line treatment in adult metastatic medulloblastoma.
Acta oncologica (Stockholm, Sweden)
Article2026
Most-cited works
by citation count (OpenAlex)- 01<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas5,933 citations2009
- 02
- 03Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma1,462 citations2020
- 04
- 05
Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/david-reardon-md-30ab18ab
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/David-A-Reardon-39924843
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/dana-farber-cancer-institute_david-reardon-md-is-doing-a-deep-dive-into-activity-7213874102464299008-IUaK
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - X / Twitter
x.com/TargetedOnc/status/693652538143457281
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Fellowship
Pediatric Hematology/Oncology, University of Michigan Hospital/C.S. Mott Children's Hospital
1992verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Residency
Pediatrics, Johns Hopkins Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Board Certified
Neuro-Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Board Certified
Pediatric Hematology/Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hstalks.com ↗
- Clinical Director
Center for Neuro-Oncology, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗ - Institute Physician
Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Professor of Medicine
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗ - Member
Cancer Immunology Program, Dana-Farber/Harvard Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗ - Member
Neuro-Oncology Program, Dana-Farber/Harvard Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗ - Principal Investigator
Cancer Research Institute (CRI) Clinical Accelerator trial of durvalumab in glioblastoma (84-patient study)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerresearch.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Cross-Field2022202320242025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- R. Wayne Rundles Award for Excellence in Clinical/Cancer Research
2007 (Duke University) -- source pages vary between "R. Wayne Rundles" and "R. K. Rundles" naming; both forms independently attested …
2007verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗
Secondary affiliations
appointments beyond the home institution- Scientific/Medical Advisory Board Member
Vivacitas Oncology Inc (Neuro-Oncology Medical Advisory Board)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivaoncology.com ↗ - Scientific Advisory Board
Immunomic Therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →immunomix.com ↗ - Scientific Advisory Board
Stemline Therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ir.stemline.com ↗ - Advisor
NEUVOGEN
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theorg.com ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Guy McKhann, MD
Emory University School of Medicine
Patrick Wen, MD
Dana-Farber Cancer Institute
Minesh Mehta, MD
Florida International University Herbert Wertheim College of Medicine
Jann Sarkaria, MD
Mayo Clinic in Rochester